Article Text

Successful treatment of refractory neuro-Behçet’s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile

Statistics from

Involvement of the central nervous system is one of the most devastating manifestations of Behçet’s disease. We describe a patient with refractory neuro-Behçet’s disease, successfully treated by infliximab, a chimeric monoclonal antibody to tumour necrosis factor α (TNFα).

A 36-year-old Japanese woman, already diagnosed as having Behçet’s disease on the basis of recurrent appearance of orogenital ulcers and bilateral uveitis, was referred to the First Department of Internal Medicine, Graduate School of Biochemical Sciences, Nagashaki University Hospital. On admission, neurological examinations showed cerebellar ataxia and pyramidal tract involvement. Examination of the patient’s cerebrospinal fluid (CSF) showed a total cell count of 576/mm3 with 56% neutrophils; protein was 128 mg/dl. A conventional therapeutic regimen, including intravenous methylprednisolone and cyclophosphamide and oral methotrexate, was used; however, she did not respond …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.